Neuropathology Flashcards

1
Q

A well circumscribed lesion was found at the conus medullaris of a 65M. Histological appearance below. Dx?

A

Myxopapillary ependymoma.
Whether obviously perivascular or not, circular profiles filled with myxoid substance are characteristic of MPE. Normally there is mucin surrounding small vascular channels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Dx?
Genetic mutation?
CNS WHO grade?
IHC?
DDX?

A

Adamantinomatous craniopharyngioma is a mixed solid and cystic squamous epithelial tumour with stellate reticulum and wet keratin, usually localized to the hypothalamic–pituitary axis and characterized by activating mutations in CTNNB1 (which encodes the b-catenin protein).
Essential criteria: localised to the sellar region, benign squamous non-keratinising epithelium, stellate reticulin or wet keratin. Desireable: Nuclear immunoreactivity for β-catenin, Mutation in CTNNB1, Absence of BRAF p.V600E mutation.
CNS WHO grade 1.
IHC: epithelial cells p63(+), HMWCK (+) (CK5/6, AE1/AE3) and LMWCK (+), PDL1 is expressed in the cyst-lining epithelium of adamantinomatous craniopharyngioma, SOX9 is widely expressed.
DDX: papillary craniopharyngioma, xanthogranuloma, Rathke cleft cyst, epidermoid and dermoid cysts, and pilocytic astrocytoma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Well circumscribed lesion in the 4th ventricle

dx?

A

Subependymoma
Glioma characterized by the clustering of uniform to mildly pleomorphic tumour cell nuclei in an abundant fibrillary matrix prone to microcystic change (CNS WHO grade 1).
Tumour cell nuclei cluster in a dense fibrillary matrix.
Below: Tumour cell nuclei are small, uniform, and without mitotic activity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

myxopapillary ependymoma

Essential & diagnostic critera
Common location:

A

Essential: Glioma with papillary structures and perivascular myxoid change or at least focal myxoid microcysts AND Immunoreactivity for GFAP AND DNA methylation profile aligned with myxopapillary ependymoma (for unresolved lesions)
Desireable: Papillary arrangements of tumour cells around vascularized fibromyxoid cores AND Location in the filum terminale or conus medullaris

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Lumbosacral lesion.

dx?
Key dx features
IHC:

A

Myxopapillary ependymoma
Glioma with papillary structures and perivascular myxoid change or at least focal myxoid microcysts AND Immunoreactivity for GFAP AND (for unresolved cases) DNA methylation profile aligned with myxopapillary ependymoma
Desireable:
Papillary arrangements of tumour cells around vascularized fibromyxoid cores
Location in the filum terminale or conus medullaris
Tumour cells are diffusely and strongly GFAP-immunoreactive.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

meningioma

  1. Subtypes
  2. Most common subtypes
A

15 subtypes, see image:
Most common subtypes: meningothelial, fibrous, and transitional meningiomas.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

meningioma grading

grading (CNS 2 and 3)

A

Chordoid and clear cell = WHO grade 2 (Higher likelihood of recurrence) independent of the criteria otherwise applied for CNS WHO grade 2 atypical meningioma;

CNS WHO grade 2:
4 to 19 mitotic figures in 10 consecutive HPF of each 0.16 mm2 (at least 2.5/mm2)
OR
Unequivocal brain invasion (not only perivascular spread or indentation of brain without pial breach)
OR
Specific morphological subtype (chordoid or clear cell; see text)
OR
At least three of the following:

· Increased cellularity

· Small cells with high N:C ratio

· Prominent nucleoli

· Sheeting (uninterrupted patternless or sheet-like growth)

· Foci of spontaneous (non-iatrogenic) necrosis

CNS WHO grade 3
20 or more mitotic figures in 10 consecutive HPF of each 0.16 mm2 (at least 12.5/mm2)
OR
Frank anaplasia (sarcoma-, carcinoma-, or melanoma-like appearance)
OR
TERT promoter mutation
OR
Homozygous deletion of CDKN2A and/or CDKN2B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

base of skull/occiptal lesion

dx?
Key features demonstrated in image

A

Chordoma (conventional type)

Typically involves the clivus, sacrococcygeal bones or vertebrae
Chords, sheets and individual cells, including cells with bubbly cytoplasm (physaliphorous cells), arranged in lobules set in a myxoid matrix
Positive for cytokeratin, EMA, S100 protein and brachyury
Poorly differentiated chordoma demonstrates loss of INI1 

Image: cells reside in abundant myxoid stroma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

saccrococcygeal lesion

dx
key featurse demonstrated by image

A

Chordoma

Typically involves the clivus, sacrococcygeal bones or vertebrae
Chords, sheets and individual cells, including cells with bubbly cytoplasm (physaliphorous cells), arranged in lobules set in a myxoid matrix
Positive for cytokeratin, EMA, S100 protein and brachyury
Poorly differentiated chordoma demonstrates loss of INI1 
	
	Image: High power view of chordoma demonstrates cells with vesicular chromatin and bubbly to clear cytoplasm.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

GB IDH WT (WHO grade 4)

molecular dx criteria sufficient for dx

A

TERT promoter mutation
EGFR amplification
gain chromosom 7/losso f 10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

meningioma subtypes

list subtypes

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

base of skull lesion

dx
Key features demonstrated
IHC

A

Meningioma WHO grade 1 (meningothelial)
Lobular growth pattern, syncytium-like appearance due to poorly defined cell borders, and frequent clear nuclear holes, with occasional intranuclear pseudoinclusions.
IHC: EMA/vimentin/SSTR2A (+)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

convexity lesion brain

dx
features demonstrated
IHC

A

Meningioma, CNS WHO grade 1, fibrous subtype

features demonstrated: Fascicular spindle cell tumour with variable collagen deposition.

IHC: EMA (weak +)/SSTR2A (+); S100 (+)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

convexity lesion brain

dx
feature demonstrated

A

meningioma, who grade 1 (transitioanl subtype)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

thoracic spine lesion

dx
molecular mutations

A

meningioma who grade1, psammomatous subtype

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

45M supratentorial lesion

dx?
Key features

A

Meningioma, CNS Who grade 2 (chordoid subtype)
Cords of small epithelioid to vacuolated tumour cells embedded in a mucin-rich matrix.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

spinal cord lesion

dx
key features

A

tancytic ependymoma, CNS WHO grade 2 (always)
Most commonly found in s/c
Have both ependymal and astrocytic features. High degree of fibrillar cellular processes resembling astrocytomas and smooth nuclei with rounded borders and salt/peppe chromatin. Pseudorosettes less common. Architecture key diagnostic features: zones with many nuclei and other zones where fibrillar cellular processes predominate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

myxopapillary ependymoma

essential and desireable dx criteria

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

cervicothoracic spinal cord

dx
IHC

A

Myxopapillary ependymoma (CNS WHO grade 2)

Prototypical is the radial arrangement of cuboidal to elongated tumour cells around hyalinized fibrovascular cores in papillary fashion, with accumulation of basophilic, myxoid material around blood vessels and in microcysts. Myxoid material, highlighted by PAS and Alcian blue positivity, is useful in the identification of examples manifesting little, if any, papillary structure and composed instead of epithelioid cells in confluent sheets.

Diffuse immunoreactivity for GFAP distinguishes myxopapillary ependymomas from metastatic carcinomas, paragangliomas, schwannomas, chordomas, and myxoid chondrosarcomas. Immunolabelling for S100 is also typical, and reactivity for CD99 and CD56 is frequent { 23455181 }. Tumour cell nuclei are not immunoreactive for OLIG2, and dot-like cytoplasmic EMA labelling is typically absent. Myxopapillary ependymomas are often labelled by the AE1/AE3 pancytokeratin cocktail, but they are generally negative for CAM5.2, CK5/6, CK7, and CK20

20
Q

15F H/O tuberous sclerosis.

Hydrocephalous. Lateral ventricle lesion

dx?
Key features?

A

subependymal giant cell astrocytoma ( CNS WHO grade 1). NB: mitoses and pallisading necrosis do not upstage it.

typically arise from the subependymal tissue of the lateral ventricles adjacent to the foramen of Monro.

In this image:
Elongated cytoplasmic profiles and a more ganglioid appearance may be a feature.

21
Q

Grading criteria for astrocytoma, IDH-mutant

A

Can be graded as CNS WHO grades 2,3 &4

CNS WHO grade 2:
A diffusely infiltrative astrocytic glioma with an IDH1 or IDH2 mutation that is well differentiated and lacks histological features of anaplasia.

Mitotic activity is not detected or very low

Microvascular proliferation , necrosis, and homozygous deletions of CDKN2A and/orCDKN2B are absent

CNS WHO grade 3:
A diffusely infiltrative astrocytic glioma with an IDH1 or IDH2 mtuation that exhibits focal or dispersed anaplasia and displays significant mitotic activity.

Microvascular proliferation, necrosis and homozygous deletions of CDKN2A and/or CDKN2B are absent

CNS WHO grade 4:
A diffusely infiltrative astrocytic glioma with an IDH1/2 mutation that exhibits microvascular proliferation or necrosis or homozygous deletion of CDKN2A and/or CDKN2B, or any combination of these features.

CNS WHO grade 3:

22
Q

Diffuse glioma, IDH-WT

Grading as per WHO

A
23
Q

ependymal tumours

Outline the WHO 2021 categories

A
NB: myxopapillary ependymoma now CNS WHO grade 2
24
Q

diagnostic criteria for chordoma

A
25
Q

List ddx for the following radiological findings in the brain:

1) Cyst with a mural nodule (4)
2) cerebellopontine angle (2)
3) Intraventricular (3)
4) Posterior fossa (3)
5) Ring enhancing lesion (5)

A

Cyst with a mural nodule (4)
1. Pilocytic astrocytoma
2. Haemangioblastoma
3. Pleomorphic xanthoastrocytoma
4. Ganglioglioma

Cerebellopontine angle (2)
1. Schwannoma
2. Meningioma

Intraventricular (3)
1. Colloid cyst
2. Subependymoma
3. Central neurocytoma

Posterior fossa (3)
1. Pilocytic astrocytoma
2. Haemangioblastoma
3. Medulloblastoma

Ring enhancing lesion (5)
1. Glioblastoma
2. Infarct
3. Abscess: tuberculoma, neurocysticercosis
4. Metastasis
5. Demyelination

26
Q

dx criteria for pleomorphic xanthoastrocytoma.
Imaging features
demographic

A

Usu cystic.
young adults.

27
Q

Intraventricular tumour, lateral ventricle.
25M

Dx:
Essential and desirable dx features

A

Central neurocytoma (CNS WHO grade 2)

is an intraventricular neuroepithelial tumour composed of uniform round cells with a neuronal immunophenotype and low proliferation index (CNS WHO grade 2).

28
Q

Which brain tumour is most frequently a/w Li Fraumeni syndrome?

A

Astrocytoma, IDH-mutant

29
Q

Grading of astrocytoma, IDH-mutant:

A
30
Q

essential and desirable dx criteria for astrocytoma, IDH-mutant

A
31
Q
A
32
Q

What is the role of testing for MGMT promoter methylation status in IDH-WT GB

A

MGMT promoter methylation status is commonly determined in IDH-wildtype glioblastomas because it provides clinically relevant information on response to chemotherapy and survival of patients treated with temozolomide.

MGMT promoter methylation is an independent prognostic marker for longer OS in glioblastoma { 19805672 } and a strong predictive marker for response to alkylating and methylating chemotherapy { 15758010 ; 25655102 ; 24068788 ; 22578793 ; 25035291 }. More than 90% of longer-term surviving patients with glioblastoma have MGMT promoter methylation 19269895 } versus only about 30% of the general patient population with glioblastoma { 25163906 }. MGMT promoter methylation also correlates with longer progression-free survival and OS in elderly patients treated with temozolomide

33
Q

essential and dx criteria for subependymoma

Image; microcytic change in subependgymoma is common

A
34
Q

well circumscribed cerebral lesion.
Dx?
Dx molecular?

A

Supratentorial ependymoma (WHO grade 2 -3 depending on brisk mitoses or vascular proliferation)

YAP1 or ZFTA fusions; NEC if another alteration is detected and NOS if unable or unfeasible to do molecular.

Molecular can be done by interphase FISH, RT-PCR–based sequencing methods, and next-generation sequencing (including transcriptome sequencing)

35
Q

cerebellar well circumscribed lesion.

Dx (+ grade):?
DDX:
Dx molecular?

A

Posterior fossa ependymoma, CNS WHO grade 3

Grade 3 -> microvascular proliferation.

Ddx: Subependymoma

Dx: If feasible, posterior fossa ependymomas should be assigned to a molecular group (PFA, PFB, or subependymoma) { 25965575 }. Absence of immunoreactivity for H3 p.K28me3 (K27me3) in the nuclei of tumour cells is a surrogate marker for PFA ependymoma { 28733933 }, but classification using DNA methylation profiling is considered the standard method, because nuclear expression of H3 p.K28me3 (K27me3) is present in both PFB tumours and subependymomas. If appropriate molecular testing was successfully performed but did not assign a molecular group, a diagnosis of posterior fossa ependymoma can be used with the suffix “NEC” { 29372318 }. An inability to perform the appropriate analysis prompts the addition of “NOS”.

36
Q

What is the Hyams grading system and what is it used for?

A

It is used to grade olfactory neuroblastoma into low and high grade. Uses the following features: architecture, mitotic activity, nuclear pleomorphism, fibrillary matrix, rosettes, necrosis.

37
Q

Define the broad categories of medulloblastoma molecular groups.

A

WNT-activated
SHH-activated TP53-wt
SHH-activated TP53 mutant
Non-WNT/non-SHH group 3
Non-WNT/non-SHH group 4.

38
Q

What stains can help you distinguish gliosis from LG glioma?

A

IDH1/IDH2 and p53. Generally, gliosis does not show IDH1/IDH2 mutations nor over expresses p53.

39
Q

cystic lesion sellar

Dx?

A

Rathke cleft cyst

40
Q

intradural cyst.
Dx?
Key features?

A

Hydatid cyst.
three layers:
Outer acellular laminated membrane.
Germinal membrane ( a transparent nucleated lining)
Protoscolices (attached to the membrane and lining it) (below)

41
Q

Describe the four molecular groups of medulloblastoma (and their predominant histomorphology)?

A

WNT-activated, SHH-activated, group 3, and group 4

42
Q

medulloblastoma, morphological subtypes: (4)

A

Classic medulloblastoma;
desmoplastic/nodular
medulloblastoma with extensive nodularity;
large cell / anaplastic medulloblastoma

43
Q

How do you molecularly define supratentorial ependymomas?

A

ZFTA-fusion positive or YAP1 fusion positivity detected by interphase FISH.

Fusion negative supratentorial ependymomas classified as NEC when no fusion detected or NOS when analysis not feasible or has been unsuccessful.

44
Q

dx criteria papillary craniopharyngioma?

A
45
Q

describe features of a SEGA?

A

Subependymal giant cell astrocytoma.

a periventricular tumour composed partly of large ganglion-like astrocytes, and strongly associated with tuberous sclerosis (TS) (CNS WHO grade 1).

Imaging: solid, partially calcified masses located in the walls of the lateral ventricles, mostly near the foramen of Monro.

Histo:
Typical appearances range from polygonal cells with abundant, glassy cytoplasm to smaller spindle cells and gemistocyte-like cells arranged in sweeping fascicles, sheets, or nests with intervening fibrillary septa. Giant pyramidal-like cells with a ganglionic-like appearance (without Nissl substance) are common. Considerable nuclear pleomorphism and multinucleated cells are frequent. Clustering of tumour cells and a perivascular rosette-like pattern resembling that of ependymoma are common features. A rich vascular stroma with frequent hyalinized vessels and infiltration by mast cells and lymphocytes, predominantly T lymphocytes, is a constant feature. Parenchymal or vascular calcifications are frequently seen .The presence of mitoses, vascular proliferation, or necrosis does not indicate anaplastic progression.

46
Q
A